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Abstract
Background: Toxoplasmic encephalitis (TE) is one of the most common opportunistic infections
in immunocompromised patients. In Cuba, despite the highly active antiretroviral therapy, TE is still
the most important cause of cerebral mass lesions in patients infected with the human
immunodeficiency virus (HIV). The detection of Toxoplasma gondii by PCR may facilitate the
diagnosis and follow-up of TE in acquired immunodeficiency syndrome (AIDS) patients by direct
identification of parasite DNA in clinical samples. The aim of the present study was to evaluate a
rapid PCR method using the B1 gene to detect T. gondii in cerebrospinal fluid (CSF) samples from
patients with suspected TE.
Methods: CSF samples from AIDS and HIV-negative patients were analyzed. Patients were divided
into two groups according to the Centre for Disease Control and Prevention (CDC) criteria for
AIDS-related TE: AIDS patients with suspected neurotoxoplasmosis and AIDS and HIV-negative
patients with other confirmed neurological diseases but no suspicions of TE. Predictive values,
diagnostic accuracy, sensitivity and specificity of the PCR B1 method were calculated.
Results: The results obtained from 190 patients showed that this assay has a good sensitivity and
specificity (83.3% and 95.7%, respectively) for the diagnosis of TE in AIDS patients.
Conclusion: PCR using the B1 gene and B22/B23 set of primers is a single, rapid and reliable
method that may be valuable for discrimination between toxoplasmosis and other central nervous
system (CNS) diseases.
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Background
Toxoplasmosis, caused by the protozoan Toxoplasma gon-
dii, is a common parasitic infection in humans which has
a cosmopolitan distribution. The prevalence of T. gondii
infection varies among different geographical regions. The
infection is characterized by non-specific symptoms with
the consequent formation of cysts that may remain in
latent form in many organs [1]. Reactivation of a latent
infection occurs in immunocompromised patients caus-
ing life-threatening disease, especially encephalitis [2,3].
In our country, toxoplasmic encephalitis (TE) is still the
most important cause of cerebral mass lesions in patients
infected with human immunodeficiency virus (HIV) [4].
Therefore, a rapid diagnosis of TE is crucial for these
patients with impaired immune functions, because early
diagnosis and treatment may improve the clinical out-
come. Although brain biopsy can establish a definitive
diagnosis of TE it is an invasive and risky procedure asso-
ciated with significant morbidity and mortality, while
only half of the TE cases are confirmed [5].
It is standard practice to establish the presumptive diagno-
sis of the disease according to the Centre for Disease Con-
trol and Prevention (CDC) criteria for acquired
immunodeficiency syndrome (AIDS)-related TE [6], but
this is not infallible. For example, anti-Toxoplasma immu-
noglobulin detection may be unreliable in immunodefi-
cient individuals, who fail to produce significant titers of
specific antibodies [7]. The clinical presentation is indis-
tinguishable from other neurologic disease frequently
occurring among these patients [8]. The so-called "typi-
cal" lesions in the brain, detected by computed tomogra-
phy (CT) or magnetic resonance imaging (MRI) are found
in about 90% of the cases. However, these highly sugges-
tive images of TE are not pathognomonic [9]. Upon the
detection of an intracerebral suggestive lesion, an empiri-
cal treatment is usually initiated. In which case, the subse-
quent clinical and radiological improvement of the
patient is considered a good criterion for diagnosis confir-
mation. Nevertheless, this approach may be used exces-
sively in areas with high T. gondii seroprevalence [10].
Since the above mentioned criteria establish only a pre-
sumptive diagnosis, the need for less invasive, more sensi-
tive, rapid and specific diagnostic methods is crucial for
immunocompromised patients. For this reason, several
studies for the diagnosis of TE employing PCR on cerebro-
spinal fluid (CSF) and blood samples have been reported
[8,11-17]. As a result, several sets of primers for different
DNA targets have been designed and each one of them
tested on a small number of biological samples from dif-
ferent body sites [18], making a general consensus pres-
ently impossible [19]. Moreover, no assays have been
sufficiently optimized and validated with a large number
of well-characterized specimens [18]. Thus, the evaluation
of each PCR in a large number of patients is extremely
important for comparative laboratory studies, especially
when the variability of conditions such as in the molecu-
lar diagnosis of toxoplasmosis is high.
The aim of this study was to evaluate a rapid PCR for TE
diagnosis, using a set of primers for the most extensively
used molecular target in a large number of CSF samples
from immunocompromised patients.
Methods
Parasite preparation
T. gondii RH tachyzoites (2 × 105/ml) were inoculated
intraperitoneally into five OF1 Swiss mice. Tachyzoites
were harvested three days later by peritoneal lavage col-
lected in 5 ml of phosphate-buffered saline (PBS), and
centrifuged at 1000 × g for 10 min. The pelleted parasites
were resuspended and washed twice in PBS. Cells were
counted in a Neubauer chamber and diluted in PBS to a
concentration of 5 × 105 cells/ml.
Patients
Approval for the study was obtained from the ethical com-
mittees of the Institute of Tropical Medicine "Pedro
Kourí" and "Miguel Enriquez" Hospital using interna-
tional criteria. Patients were informed about the study and
written informed consent was obtained from each one of
them or their closest relative. Clinical, immunological,
radiological and laboratory data were collected from clin-
ical charts.
The study included a total of 132 AIDS patients admitted
to the clinical wards at the Institute of Tropical Medicine
"Pedro Kourí", and 58 samples of HIV-negative patients
from "Miguel Enriquez" Hospital, both in Havana, Cuba.
Neurological symptoms were present in all patients.
Before specific therapy was started, a spinal tap was per-
formed, to collect 1 ml of CSF from each patient, and sam-
ples were stored at -20°C until analyzed.
Patients were divided into two groups. Group I (n = 48)
consisted of AIDS patients with suspected neurotoxoplas-
mosis according to the CDC criteria for AIDS-related TE
[6] which includes the following clinical and radiological
features: I) recent onset of a consistent focal neurological
abnormality with intracranial disease or reduced level of
consciousness; II) a lesion having a mass effect evidenced
by CT imaging and III) serum antibody to T. gondii or suc-
cessful response to treatment of toxoplasmosis. Group II
(n = 142) consisted of 84 patients with other AIDS-related
disorders (25 neurocryptococcosis, 11 tuberculosis, 6
non-Hodgkin lymphoma, 9 viral meningitis, 12 HIV
encephalitis, 21 active febrile illness not suspected of
being toxoplasmosis) and 58 HIV-negative patients with
inflammatory or non-inflammatory neurological disease.Cerebrospinal Fluid Research 2009, 6:2 http://www.cerebrospinalfluidresearch.com/content/6/1/2
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DNA extraction
For the DNA to be used as positive control for PCR, the
phenol-chloroform-isoamyl alcohol (25:24:1) extraction
method was employed [20] on a previously-counted pel-
let of RH strain T. gondii cells. All CSF samples were indi-
vidually concentrated by centrifugation at 3000 × g for 10
min. Sediments were re-suspended in 40 μl of lysis buffer
(10 mM Tris-HCl pH 8.3, 1.5 mM MgCl2, 50 mM KCl, 0.1
mg of gelatin per ml, 0.5% Tween 20, 20 μg of proteinase
K (Promega, Madison, USA) and incubated at 55°C, with
shaking for 90 min. After inactivating the proteinase K at
94°C for 10 min, the tubes were centrifuged at 10,000 × g
for 5 min, and the supernatants collected [21,22].
PCR analytical sensitivity and specificity
To determine the PCR sensitivity, two-fold serial dilutions
ranging from 5 × 105 to 1 cell of the parasite (RH strain)
were prepared and DNA was extracted as previously
described [21,22]. The DNA obtained was used for PCR
under the same conditions as for clinical samples. Specif-
icity was determined by PCR amplification of DNA
extracted from yeasts (Cryptoccocus neoformans, Candida
albicans, Candida parapsilopsis), gram positive cocci (Sta-
phylococcus aureus, Staphylococcus epidermidis, Streptoccocus
pneumoniae), gram negative rods (Serratia marcescens,
Pseudomona aeruginos, Escherichia coli, Haemophilus influen-
zae), gram negative coccus (Neisseria meningitides) and
herpes virus (Herpes simplex, Epstein Barr, Varicela Zoster,
Cytomegalovirus).
Detection of T. gondii DNA by PCR
From the CSF samples, T. gondii DNA was detected by the
amplification of a fragment of 115-bp of B1 gene [23],
using primers B22 and B23 as previously described by Bre-
tagne et al. [24]. The reaction conditions were tested using
a large number of modifications to optimize the PCR con-
ditions: temperature for primer annealing (58°C, 59°C,
60°C), MgCl2 concentration (1.5, 2.0, 3.0, 4 mM), Taq
DNA polymerase concentration (0.5, 1.0, 1.5, 2.0, 3.0 U)
and primer concentration (0.05, 0.1, 0.2, 0.3, 0.4 μM).
Consequently the proportion of DNA from CSF samples
in the mixture reaction was also optimized. The opti-
mized amplification was performed in 25 μl of reaction
mixture containing 10 mM Tris-HCl, pH 8.5, 50 mM KCl,
1.5 mM MgCl2, 0.2 μM of each primer (B22 and B23), 200
μM of each deoxynucleoside triphosphate and 1.5 U Taq
DNA polymerase (Promega). Ten microliters of extracted
DNA from CSF samples were added as template. The PCR
conditions were 94°C for 5 min, followed by 35 cycles of
94°C for 30 s, 59°C for 30 s, and 72°C for 30 s and a last
extension step at 72°C for 10 min.
Each amplification assay contained two negative controls
(ultrapure water and a negative control for DNA extrac-
tion) and one positive control (DNA extracted from RH T.
gondii tachyzoites). Physical separation for mixture prepa-
ration, DNA extraction and visualization of PCR products
were carried out and decontamination procedures were
used in all areas to avoid contamination by amplicons.
The PCR products were analyzed by 2% agarose gel elec-
trophoresis in tris-borate-EDTA (TBE) buffer and stained
with ethidium bromide (0.5 mg/ml). The DNA fragments
were visualized under UV illumination.
Clinical samples with positive PCR results were tested
twice. For the negative samples, an inhibition test was per-
formed to discard the presence of inhibitors. (i.e., DNA
equivalent to 5 cells of T. gondii RH was added to the neg-
ative DNA sample).
Statistical analysis
Predictive values, diagnostic accuracy, sensitivity and spe-
cificity of the PCR B1 method were calculated using a 2 ×
2 contingency table and recognized formulae [25-27] in
which the CDC criteria for TE were used as a "gold stand-
ard".
Results
To determine the usefulness of the PCR for the diagnosis
of TE in immunocompromised patients, 190 CSF samples
from AIDS and HIV-negative patients were studied. After
optimization of PCR conditions (data not shown), the
assay was sensitive enough to detect up to one tachyzoite
of T. gondii. A representative agarose gel of PCR products
is shown in Figure 1. In order to investigate the analytical
specificity of PCR, DNA from a variety of microorganisms
that could potentially be present in the CSF of AIDS
patients was used as target for the PCR reaction. No ampli-
fication product was observed when DNA from these
specimens was present in the mixture reaction, thus dem-
Agarose gel electrophoresis analysis of PCR amplifications  products performed with different numbers of tachyzoites Figure 1
Agarose gel electrophoresis analysis of PCR amplifi-
cations products performed with different numbers 
of tachyzoites. Lane MWM: Molecular Weight Marker 50 
bp (Amersham, USA). Lane NC: Negative Control. Lane PC: 
Positive control.Cerebrospinal Fluid Research 2009, 6:2 http://www.cerebrospinalfluidresearch.com/content/6/1/2
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onstrating the absolute specificity of the set of PCR prim-
ers used (data not shown).
PCR diagnostic sensitivity and specificity were evaluated
using the CDC criteria as the gold standard for AIDS-
related TE to detect T. gondii central nervous system (CNS)
infection in patients, with and without suspected infec-
tion. The PCR results are shown in Table 1. In group I, 40/
48 patients with suspected TE had PCR positive results. In
group II, corresponding to patients without suspected TE,
six samples produced positive results while the remaining
136 (95.7%) resulted negative. None of these positive
samples were from HIV-negative patients.
The data represent a diagnostic sensitivity of 83.3% and a
95.7% of specificity. The positive predictive value of the
assay was 86.9% while negative predictive value was
94.4%. The diagnostic accuracy was 92.6%, indicating the
assay is reliable.
Discussion
The introduction of Highly Active Antiretroviral Therapy
(HAART) has resulted in the decline of the incidence of
opportunistic infections in the CNS in AIDS patients [5].
Particularly in Cuba, despite the universal use of HAART,
TE is still the most important cause of cerebral mass
lesions among HIV-infected patients [4]. Although a
definitive diagnosis of the disease relies on the identifica-
tion of parasites by histopathology, the clinical and radi-
ological data could be complemented by a less invasive
approach [17] that confirms the presence of parasites in
body fluids, resulting in a better clinical management of
the disease. The selection of the primers is also an essen-
tial step for successful PCR. Chabbert et al. [28] previously
reported the high sensitivity of the B22 and B23 set of
primers when compared with other T. gondii sequence
primers. Due to their higher sensitivity, specificity and
practicability, the use of these primers was recommended
for the detection of T. gondii DNA in immunocompro-
mised patients where Brazilian researchers found they
gave a good diagnostic sensitivity [16,17]. The B1 gene has
been the most widely used target for the diagnosis of tox-
oplasmosis [19]. Hence, it was expected that the B1 PCR
employed here would prove to be useful for the detection
of T. gondii CNS infection. The evaluation of the large
cohort used in this study adds weight to this hypothesis.
The results of the analytical sensitivity assay (1 parasite)
was similar to previous studies that used sets of primers
for B1 gene and was able to detect either a single organism
from a crude cell lysate [23,29] or 10 tachyzoites in pres-
ence of 100,000 human leukocytes [23]. These results
show that very small numbers of T. gondii can be detected.
The diagnostic sensitivity found in this study was 83.3%
(Table 1). This means that 40 patients out of 48 with sus-
pected neurotoxoplasmosis gave positive results for the
presence of T. gondii, demonstrating that PCR is a diagnos-
tic technique with relatively high sensitivity for TE in CSF
samples. Eight AIDS patients with suspected TE had nega-
tive results and in one of them the necropsy confirmed the
diagnosis of TE. None of these patients received treatment
before the spinal tap. Therapy is an important element for
the sensitivity of PCR, since previous studies reported that
anti-Toxoplasma therapy decreases diagnostic sensitivity,
especially when the samples are collected after the first
week of treatment [30].
The sensitivities previously reported for TE diagnosis from
CSF range widely in value (17% – 100%) with an average
of 59% (97/164 patients with TE from 17 studies) [19].
The sensitivity obtained in our work corresponds to the
range reported for CSF and was superior to several studies
that use CSF and nested reactions for B1 gene [12,31].
Also, it is noteworthy that the sensitivity of a PCR depends
on many factors such as physicochemical conditions of
the reaction, the concentration and nature of DNA target,
the selected PCR primers and the nucleic acid extraction
method [32]. In our case, optimization of the PCR condi-
tions was carefully carried out enhancing the analytical
sensitivity and specificity of the assay. An additional
advantage is the frequency in which the B1 gene is present
in the parasite genome [33]. Is well known that the
number of copies of the DNA target in the genome of
interest is an essential factor for the assay sensitivity and
also that the use of the same primers does not necessarily
ensure identical results for different laboratories [32]. In
Table 1: Relation between the PCR results from CSF samples and the presence or absence of toxoplasmic encephalitis (TE).
PCR results Patients with TE (I) Patients without TE (II) Total No. of samples
Positive PCR 40(83.3%)1 64 6
Negative PCR 8 136 (95.7%)2 144
Total No. of samples 48 142 190
1 Diagnostic sensitivity
2 Diagnostic specificityCerebrospinal Fluid Research 2009, 6:2 http://www.cerebrospinalfluidresearch.com/content/6/1/2
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relation to this, a study carried out in Brazil by Vidal et al.
[16] used CSF samples from immunocompromised
patients and the same set of primers for the B1 gene as
used here. They reported 100% sensitivity while our sen-
sitivity for the present study was lower, even though sim-
ilar PCR conditions were used. On the other hand the
above mentioned study included 12 patients, while we
used samples from four times more patients with TE. Nev-
ertheless, the DNA extraction methods differed between
the laboratories and this fact may play an important role
in the assay performances and significantly influence the
assay sensitivity. In our experience, as previously reported,
the DNA extraction protocol was chosen after comparing
four different extraction methods [22]. In comparison
with other in-house DNA extraction methods the protocol
here used is rapid, reproducible, and simple and it could
be recommended for routine PCR diagnosis of TE in
places with limited resources.
The laboratory conditions are crucial to raise the sensitiv-
ity and specificity of the PCR technique, especially when
it is used on clinical specimens. For this reason, an inhibi-
tion test was carried out for every sample producing nega-
tive results in order to rule out the presence of PCR
inhibitors. Moreover, negative controls were used to check
for contamination and all the necessary cautions were
taken in order to prevent possible risks of contamination
that frequently happens in this kind of reaction.
As for the dignostic specificity, all six sample from AIDS
patients without suspected TE with positive results, corre-
sponded to patients presenting with other AIDS related
diseases but without clinical or radiological evidence of
cerebral toxoplasmosis upon admission. Although specif-
icity of PCR in the diagnosis of TE has been extremely high
in most of reports, false positive results have been
described [16,17,34,35], particularly among immuno-
compromised patients, for whom it has been proposed
that parasitemia may exist prior to, or during the course of
cerebral toxoplasmosis [18]. In our case, clinical surveil-
lance of these six patients was not made and the possibil-
ity of subsequent TE could not be excluded, making the
results inconclusive. It is possible that the sporadic break-
down of tissue cysts may provide enough DNA in the CSF
for parasite detection, in contrast to the large amount of
parasite DNA that is found in evident TE [34]. These six
individuals could have still some immunological capacity
to destroy parasites released from the sporadic breakdown
of cysts, and so prevent the reactivation of TE.
Conclusion
PCR using the B22 and B23 primer sets for the diagnosis
of TE in AIDS patients is a rapid, simple, reliable, sensitive
and specific method, and can be used as a practical and
alternative tool for the diagnosis of TE in immunocom-
promised patients. The method is easy to perform and less
prone to contamination compared with nested PCR reac-
tion and will help patients to gain the benefit of early anti-
Toxoplasma treatment.
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